LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy.

    Nowicki, Theodore S / Peters, Cole W / Quiros, Crystal / Kidd, Conner K / Kawakami, Moe / Klomhaus, Alexandra M / Baselga-Carretero, Ignacio / Kaplan-Lefko, Paula / Macabali, Mignonette H / Perez Garcilazo, Ivan / Berent-Maoz, Beata / Comin-Anduix, Begoña / Ribas, Antoni

    Cancer immunology research

    2023  Volume 11, Issue 12, Page(s) 1589–1597

    Abstract: Transgenic T-cell receptor (TCR) T cell-based adoptive cell therapies for solid tumors are associated with dramatic initial response rates, but there remain many instances of treatment failure and disease relapse. The association of infusion product ... ...

    Abstract Transgenic T-cell receptor (TCR) T cell-based adoptive cell therapies for solid tumors are associated with dramatic initial response rates, but there remain many instances of treatment failure and disease relapse. The association of infusion product cytokine profiles with clinical response has not been explored in the context of TCR T-cell therapy products. Single-cell antigen-dependent secretomic and proteomic analysis of preinfusion clinical TCR T-cell therapy products revealed that TNFα cytokine functionality of CD8+ T cells and phospho-STAT3 signaling in these cells were both associated with superior clinical responsiveness to therapy. By contrast, CD4+ T-helper 2 cell cytokine profiles were associated with inferior clinical responses. In parallel, preinfusion levels of IL15, Flt3-L, and CX3CL1 were all found to be associated with clinical response to therapy. These results have implications for the development of therapeutic biomarkers and identify potential targets for enrichment in the design of transgenic TCR T-cell therapies for solid tumors.
    MeSH term(s) Animals ; Humans ; Mice ; Tumor Necrosis Factor-alpha ; Proteomics ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/metabolism ; Cytokines ; Animals, Genetically Modified ; Neoplasms ; Cell- and Tissue-Based Therapy ; Mice, Transgenic ; STAT3 Transcription Factor
    Chemical Substances Tumor Necrosis Factor-alpha ; Receptors, Antigen, T-Cell ; Cytokines ; STAT3 protein, human ; STAT3 Transcription Factor
    Language English
    Publishing date 2023-10-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2732489-8
    ISSN 2326-6074 ; 2326-6066
    ISSN (online) 2326-6074
    ISSN 2326-6066
    DOI 10.1158/2326-6066.CIR-23-0577
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Remodeling of the tumor microenvironment through PAK4 inhibition sensitizes tumors to immune checkpoint blockade.

    Abril-Rodríguez, Gabriel / Torrejon, Davis Y / Karin, Daniel / Campbell, Katie M / Medina, Egmidio / Saco, Justin D / Galvez, Mildred / Champhekar, Ameya S / Perez-Garcilazo, Ivan / Baselga-Carretero, Ignacio / Singh, Jas / Comin-Anduix, Begoña / Puig-Saus, Cristina / Ribas, Antoni

    Cancer research communications

    2022  Volume 2, Issue 10, Page(s) 1214–1228

    Abstract: PAK4 inhibition can sensitize tumors to immune checkpoint blockade (ICB) therapy, however, the underlying mechanisms remain unclear. We report that PAK4 inhibition reverses immune cell exclusion by increasing the infiltration of CD8 T cells and ... ...

    Abstract PAK4 inhibition can sensitize tumors to immune checkpoint blockade (ICB) therapy, however, the underlying mechanisms remain unclear. We report that PAK4 inhibition reverses immune cell exclusion by increasing the infiltration of CD8 T cells and CD103
    MeSH term(s) Animals ; Mice ; Immune Checkpoint Inhibitors/pharmacology ; Tumor Microenvironment/genetics ; CD8-Positive T-Lymphocytes ; Melanoma/drug therapy ; Antigens, Neoplasm/pharmacology
    Chemical Substances Immune Checkpoint Inhibitors ; Antigens, Neoplasm
    Language English
    Publishing date 2022-10-19
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 2767-9764
    ISSN (online) 2767-9764
    DOI 10.1158/2767-9764.crc-21-0133
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Neoantigen-targeted CD8

    Puig-Saus, Cristina / Sennino, Barbara / Peng, Songming / Wang, Clifford L / Pan, Zheng / Yuen, Benjamin / Purandare, Bhamini / An, Duo / Quach, Boi B / Nguyen, Diana / Xia, Huiming / Jilani, Sameeha / Shao, Kevin / McHugh, Claire / Greer, John / Peabody, Phillip / Nayak, Saparya / Hoover, Jonathan / Said, Sara /
    Jacoby, Kyle / Dalmas, Olivier / Foy, Susan P / Conroy, Andrew / Yi, Michael C / Shieh, Christine / Lu, William / Heeringa, Katharine / Ma, Yan / Chizari, Shahab / Pilling, Melissa J / Ting, Marc / Tunuguntla, Ramya / Sandoval, Salemiz / Moot, Robert / Hunter, Theresa / Zhao, Sidi / Saco, Justin D / Perez-Garcilazo, Ivan / Medina, Egmidio / Vega-Crespo, Agustin / Baselga-Carretero, Ignacio / Abril-Rodriguez, Gabriel / Cherry, Grace / Wong, Deborah J / Hundal, Jasreet / Chmielowski, Bartosz / Speiser, Daniel E / Bethune, Michael T / Bao, Xiaoyan R / Gros, Alena / Griffith, Obi L / Griffith, Malachi / Heath, James R / Franzusoff, Alex / Mandl, Stefanie J / Ribas, Antoni

    Nature

    2023  Volume 615, Issue 7953, Page(s) 697–704

    Abstract: Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T ... ...

    Abstract Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells
    MeSH term(s) Humans ; Antigens, Neoplasm/immunology ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Immunotherapy ; Melanoma/drug therapy ; Melanoma/genetics ; Melanoma/immunology ; Melanoma/pathology ; Receptors, Antigen, T-Cell/immunology ; Receptors, Antigen, T-Cell/metabolism ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; HLA Antigens/immunology ; Neoplasm Metastasis ; Precision Medicine ; Gene Editing ; CRISPR-Cas Systems ; Mutation
    Chemical Substances Antigens, Neoplasm ; Receptors, Antigen, T-Cell ; Immune Checkpoint Inhibitors ; HLA Antigens ; PDCD1 protein, human
    Language English
    Publishing date 2023-03-08
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 120714-3
    ISSN 1476-4687 ; 0028-0836
    ISSN (online) 1476-4687
    ISSN 0028-0836
    DOI 10.1038/s41586-023-05787-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Autoantibody Landscape in Patients with Advanced Prostate Cancer.

    Chen, William S / Haynes, Winston A / Waitz, Rebecca / Kamath, Kathy / Vega-Crespo, Agustin / Shrestha, Raunak / Zhang, Minlu / Foye, Adam / Baselga Carretero, Ignacio / Perez Garcilazo, Ivan / Zhang, Meng / Zhao, Shuang G / Sjöström, Martin / Quigley, David A / Chou, Jonathan / Beer, Tomasz M / Rettig, Matthew / Gleave, Martin / Evans, Christopher P /
    Lara, Primo / Chi, Kim N / Reiter, Robert E / Alumkal, Joshi J / Ashworth, Alan / Aggarwal, Rahul / Small, Eric J / Daugherty, Patrick S / Ribas, Antoni / Oh, David Y / Shon, John C / Feng, Felix Y

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2020  Volume 26, Issue 23, Page(s) 6204–6214

    Abstract: Purpose: Autoantibody responses in cancer are of great interest, as they may be concordant with T-cell responses to cancer antigens or predictive of response to cancer immunotherapies. Thus, we sought to characterize the antibody landscape of metastatic ...

    Abstract Purpose: Autoantibody responses in cancer are of great interest, as they may be concordant with T-cell responses to cancer antigens or predictive of response to cancer immunotherapies. Thus, we sought to characterize the antibody landscape of metastatic castration-resistant prostate cancer (mCRPC).
    Experimental design: Serum antibody epitope repertoire analysis (SERA) was performed on patient serum to identify tumor-specific neoepitopes. Somatic mutation-specific neoepitopes were investigated by associating serum epitope enrichment scores with whole-genome sequencing results from paired solid tumor metastasis biopsies and germline blood samples. A protein-based immunome-wide association study (PIWAS) was performed to identify significantly enriched epitopes, and candidate serum antibodies enriched in select patients were validated by ELISA profiling. A distinct cohort of patients with melanoma was evaluated to validate the top cancer-specific epitopes.
    Results: SERA was performed on 1,229 serum samples obtained from 72 men with mCRPC and 1,157 healthy control patients. Twenty-nine of 6,636 somatic mutations (0.44%) were associated with an antibody response specific to the mutated peptide. PIWAS analyses identified motifs in 11 proteins, including NY-ESO-1 and HERVK-113, as immunogenic in mCRPC, and ELISA confirmed serum antibody enrichment in candidate patients. Confirmatory PIWAS, Identifying Motifs Using Next-generation sequencing Experiments (IMUNE), and ELISA analyses performed on serum samples from 106 patients with melanoma similarly revealed enriched cancer-specific antibody responses to NY-ESO-1.
    Conclusions: We present the first large-scale profiling of autoantibodies in advanced prostate cancer, utilizing a new antibody profiling approach to reveal novel cancer-specific antigens and epitopes. Our study recovers antigens of known importance and identifies novel tumor-specific epitopes of translational interest.
    MeSH term(s) Aged ; Antigens, Neoplasm/immunology ; Autoantibodies/blood ; Autoantibodies/immunology ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/immunology ; Case-Control Studies ; Epitopes/immunology ; Follow-Up Studies ; Humans ; Male ; Mutation ; Prognosis ; Prospective Studies ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/immunology ; Prostatic Neoplasms/pathology
    Chemical Substances Antigens, Neoplasm ; Autoantibodies ; Biomarkers, Tumor ; Epitopes
    Language English
    Publishing date 2020-09-23
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-20-1966
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top